Human Papillomavirus (HPV) Vaccine Market Forecast to 2028

Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (9-Valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and Distribution Channel (Doctors Office, Community Health Clinics, School-Based Health Centers, Health Departments, Hospitals, and Others)

Report Code : TIPRE00029411 | Region : Global | Industry : Pharmaceuticals | Published Date : 16/Jun/2022

The global human papillomavirus (HPV) vaccine market was valued at US$ 4,273.84 million in 2022 and is projected to reach US$ 5,730.50 million by 2028; it is expected to grow at a CAGR of 5.0% from 2022 to 2028.

The growth of the human papillomavirus (HPV) vaccine market is mainly attributed to factors such as increase in prevalence of HPV associated diseases and rise in initiatives taken by global health organizations. However, the high cost of HPV vaccines hinders the overall market growth.

Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the global strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the world must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer.

Further, in 2014, the American Cancer Society and the Centers for Disease Control and Prevention (CDC) established the National HPV Vaccination Roundtable dedicated to reducing the incidence of and mortality from HPV-associated cancer in the US alone. Additionally, the American Cancer Society's Mission: HPV Cancer Free is a public health initiative that aims at eliminating vaccine-preventable HPV cancers as a public health problem, starting with cervical cancer. Its goal is to reach an annual vaccination rate of 80% of 13-year-olds in the US by 2026.

In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. 27 countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer globally, such as Malawi, the United Republic of Tanzania, Uganda, Zambia, and Zimbabwe, initiated the Gavi HPV vaccine program. All these initiatives are aiding the global HPV vaccines market substantially.

The COVID-19 pandemic is likely to have longer-term consequences on the HPV vaccine business. Many primary care clinics in the US have continued to operate at a reduced capacity to abide by social distancing measures and adopt stringent cleaning protocols. A reduction in in-person office visits limits opportunities for providers of vaccine to discuss and deliver vaccines. Barriers in transportation are likely to harm HPV vaccination; pharma and biotech companies traditionally find it difficult to market vaccines among the masses because of resistance received from parents and the absence of widespread awareness about school entry requirements that support other adolescent vaccines. The available evidence indicates that the COVID-19 pandemic has dramatically disrupted the delivery of HPV vaccines in 2020 and 2021. Early reports by CDC, suggest that ordering and billing dropped by >70% in March 2020. Furthermore, a 25–50% decrease in HPV vaccine orders continued in June 2020, in contrast to other early childhood-vaccine orders that resurged to near pre-pandemic levels. Although the revival of the HPV vaccine market is in progress, available data suggest that a short-term decline in HPV vaccination coverage will be substantial, and the demand for HPV vaccines will grow across North America in long term.

The COVID-19 pandemic placed health systems in Europe under unprecedented strain and disrupted the routine vaccination programs, which underscored the importance of resilient and sustainable immunization. The global crisis also hampered the HPV vaccination programs. Students in Europe were unable to attend school, uncertainties associated with the pandemic and subsequently affected operations in the education sector have led to delays in the administration of certain school-based vaccines. In Greece, the Hellenic Pediatric Society reported a 45 % fall in the number of pupils from the age group of 11–16 who received HPV vaccine doses in 2020. This urges the maintenance of routine immunization and recovery of coverage rates. The ambitious Beating Cancer Plan of Europe set a goal to vaccinate at least 90% of girls and significantly more boys by 2030 in school with HPV vaccine. With the subsequent decrease in COVID-19 cases in Europe, the HPV vaccination rate increased after June 2021 as summer and spring are the major seasons where people are affected by HPV.

The COVID-19 pandemic had significantly impacted the human papillomavirus (HPV) vaccine market. Human papillomavirus (HPV) vaccination programs have been severely impacted by the pandemic. Owing to the pandemic, 872 million students worldwide are unable to attend school due to the subsequent school closures, which have delayed delivery and administration of certain school-based vaccinations.

Based on type, the human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. In 2022, the quadrivalent HPV vaccine segment holds the largest market share. However, the market for the 9-valent HPV vaccine segment is expected to witness rapid growth during 2022–2028. With HPV vaccination showing positive outcomes, the new 9-valent HPV vaccine was developed to increase protection against 5 more strains (i.e., HPV types 31, 33, 45, 52, and 58). The 9-valent HPV vaccine offers more protection against HPV than the quadrivalent HPV vaccine and is considered as a safer option.

Based on dosage, the human papillomavirus (HPV) vaccine market is segmented into 2 dose and 3 dose. In 2022, the 2 dose segment accounts for a larger market share. However the 3-dose segment is anticipated to register a higher CAGR in the market during the forecast period.

The global human papillomavirus (HPV) vaccine market, based on age, is segmented into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment holds a larger share of the market in 2022, and the same segment is anticipated to register a higher CAGR during the forecast period.

In terms of application, the global human papillomavirus (HPV) vaccine market is segmented into HPV-attributable cancers and genital warts. The HPV-attributable cancers segment holds a larger share of the market in 2022, and the same segment is anticipated to register a higher CAGR during the forecast period.

On the basis of distribution channel, the global human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held the largest share of the market in 2022, and the school based health centers segment is anticipated to register the highest CAGR in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American Cancer Society and Gavi, The Vaccine Alliance, Australian Cervical Cancer Foundation's (ACCF) are a few of the major primary and secondary sources referred to while preparing the report of the global human papillomavirus (HPV) vaccine market.

Growing Number of HPV Awareness Programs to Create Growth Opportunities for Global Human Papillomavirus (HPV) Vaccine Market during 2022–2028

According to our new research study on “Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Dosage, Age, Application, and Distribution Channel,” the market is expected to grow from US$ 4,273.84 million in 2022 to US$ 5,730.50 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2022 to 2028. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the global market growth.

Factors such as increase in prevalence of HPV associated diseases and rise in initiatives by global health organizations drive the overall human papillomavirus (HPV) vaccine market growth. However, the high cost of HPV vaccines hinders the market growth.

The increase in programs for HPV awareness is one of the effective strategies to increase the vaccination uptake and eliminate HPV-associated cancers.

Dana-Farber Cancer Institute, Boston, US, has initiated the HPV and Related Cancers Outreach Program, which aims to reduce the HPV-related cancer burden in the community through education and vaccination. The outreach program has been developed to address common barriers to vaccination. Through workshops with the City of Boston and the Boston Public Health Commission, youth-serving organizations, Boston Public Schools, Area Health Education Centers organizations, and faith-based and other community-based organizations, people in Boston have been educated about it.

Australian Cervical Cancer Foundation's (ACCF) HPV & Me program is an awareness program that empowers high school students with preventive strategies to eliminate the risks associated with Human Papillomavirus (HPV).

Additionally, in collaboration with computer scientists, HPV-related Epidemiological Research Unit, Norway, developed an innovative approach to communicate the importance of cervical cancer prevention to girls, women, boys, and men of different ages.

Therefore, the market in developing countries is likely to show high growth potential over the next few years.

North America dominated the human papillomavirus (HPV) vaccine market due to the increasing HPV infections and the growing initiatives by governments and institutions for HPV vaccination drive. The US, Canada, and Mexico are witnessing a sequential change in the market. The US accounts the largest share of the regional human papillomavirus (HPV) vaccine market in 2022. Sexual transmitted infection (STI) is the most common infection caused by HPV in the US, and it is often acquired soon after initiating sexual activity. More than 43% of American adults aged 18–59 are infected with genital HPV, with higher rates among men (45%) than women (40%). HPV-related cancers have increased significantly in the past 15 years. In 2015, 43,000 people developed an HPV-related cancer, whereas the count was 30,000 in 1999. While HPV-related cervical and vaginal cancer rates have decreased in recent years, rates for oropharyngeal and anal HPV-related cancers have increased. This increase in HPV infections in the US is mainly driving the growth of the regional market.

The COVID-19 pandemic is likely to have long-term consequences on the HPV vaccine business. Many primary care clinics in the US have continued to operate at a reduced capacity to abide by social distancing measures and adopt stringent cleaning protocols. A reduction in in-person office visits limits opportunities for providers of vaccine to discuss and deliver vaccines. Barriers in transportation are likely to harm HPV vaccination; pharma and biotech companies traditionally find it difficult to market vaccines among the masses because of resistance received from parents and the absence of widespread awareness about school entry requirements that support other adolescent vaccines. The available evidence indicates that the COVID-19 pandemic has dramatically disrupted the delivery of HPV vaccines in 2020 and 2021. Early reports by CDC, suggest that ordering and billing dropped by >70% in March 2020. Furthermore, a 25–50% decrease in HPV vaccine orders continued in June 2020, in contrast to other early childhood-vaccine orders that resurged to near pre-pandemic levels. Although the revival of the HPV vaccine market is in progress, available data suggest that a short-term decline in HPV vaccination coverage will be substantial, and the demand for HPV vaccines will grow in North America in long term.

GSK; Innovax; Walvax; Serum Institute of India Pvt., Ltd.; Vaccitech; Innovio Pharmaceuticals; Merck & Co., Inc.; 2A Pharm; ChengDu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and BioLeaders are among the leading companies operating in the global human papillomavirus (HPV) vaccine market.

Global Human Papillomavirus (HPV) Vaccine Market, by Region, 2022 (%)

Source: The Insight Partners Analysis

By geography, the human papillomavirus (HPV) vaccine market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, Southeast Asia, New Zealand, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Chile, Guatemala, Peru, Colombia, and the Rest of South & Central America).

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Human Papillomavirus (HPV) Vaccines Market – By Type

1.3.2 Global Human Papillomavirus (HPV) Vaccines Market – By Dosage

1.3.3 Global Human Papillomavirus (HPV) Vaccines Market – By Age

1.3.4 Global Human Papillomavirus (HPV) Vaccines Market – By Application

1.3.5 Global Human Papillomavirus (HPV) Vaccines Market – By Distribution Channel

1.3.6 Global Human Papillomavirus (HPV) Vaccines Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Human Papillomavirus (HPV) Vaccine Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East and Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increase in Prevalence of HPV Associated Diseases

5.1.2 Initiatives Taken by Global Health Organizations

5.2 Market Restraints

5.2.1 High Cost of HPV Vaccines

5.3 Market Opportunities

5.3.1 Growing Number of HPV Awareness Programs

5.4 Future Trends

5.4.1 Advancements in HPV Diagnostics Tests

5.5 Impact Analysis

6. Human Papillomavirus (HPV) Vaccine Market– Global Analysis

6.1 Global Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis

6.2 Global Human Papillomavirus (HPV) Vaccine Market, By Geography - Forecast and Analysis

6.3 Global Human Papillomavirus (HPV) Vaccine Market – Market Potential Analysis, By Region

6.4 Growth Strategy Analysis

6.5 Performance of Key Players

6.5.1 Merck & Co., In.

6.5.2 GSK

7. Global Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast To 2028– by Type

7.1 Overview

7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)

7.3 9-valent HPV vaccine

7.3.1 Overview

7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.4 Quadrivalent HPV vaccine

7.4.1 Overview

7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.5 Bivalent HPV Vaccine

7.5.1 Overview

7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)

8. Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 by Dosage

8.1 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)

8.2 2 Dose

8.2.1 Overview

8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

8.3 3 Dose

8.3.1 Overview

8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9. Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 by Age

9.1 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)

9.2 9 to 14 Years

9.2.1 Overview

9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9.3 to 45 Years

9.3.1 Overview

9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10. Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 by Application

10.1 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)

10.2 HPV-attributable Cancer

10.2.1 Overview

10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10.3 Genital Warts

10.3.1 Overview

10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11. Global Human Papillomavirus (HPV) Vaccine Market Analysis and Forecast to 2028 – by End User

11.1 Overview

11.2 Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)

11.3 Doctor Office

11.3.1 Overview

11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)

11.4 Community Health Clinics

11.4.1 Overview

11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)

11.5 School-based Health Centers

11.5.1 Overview

11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)

11.6 Health Departments

11.6.1 Overview

11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)

11.7 Hospitals

11.7.1 Overview

11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)

11.8 Others

11.8.1 Overview

11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)

12. Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 Geographical Analysis

12.1 North America: Human Papillomavirus (HPV) Vaccine Market

12.1.1 Overview

12.1.2 North America: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.3 North America: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.4 North America: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.5 North America: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.6 North America: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.7 North America: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.8 North America: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

12.1.8.1 US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.1 Overview

12.1.8.1.2 US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.3 US: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.8.1.4 US: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.8.1.5 US: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.8.1.6 US: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.8.1.7 US: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.8.2 Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.1 Overview

12.1.8.2.2 Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.3 Canada: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.8.2.4 Canada: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.8.2.5 Canada: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.8.2.6 Canada: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.8.2.7 Canada: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.8.3 Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.1 Overview

12.1.8.3.2 Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.3 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.8.3.4 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.8.3.5 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.8.3.6 Mexico: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.8.3.7 Mexico: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.2 Europe: Human Papillomavirus (HPV) Vaccine Market

12.2.1 Overview

12.2.2 Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.3 Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.4 Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.5 Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.6 Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.7 Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8 Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

12.2.8.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.1.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.1.2 Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.1.3 Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.1.4 Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.1.5 Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.1.6 Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.2 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.2.1 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.2.2 France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.2.3 France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.2.4 France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.2.5 France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.2.6 France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.3 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.3.1 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.3.2 UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.3.3 UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.3.4 UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.3.5 UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.3.6 UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.4 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.4.1 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.4.2 Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.4.3 Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.4.4 Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.4.5 Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.4.6 Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.5 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.5.1 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.5.2 Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.5.3 Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.5.4 Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.5.5 Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.5.6 Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.6 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.6.1 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.6.2 Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.6.3 Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.6.4 Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.6.5 Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.6.6 Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.7 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.7.1 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.7.2 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.7.3 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.7.4 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.7.5 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.7.6 Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.2.8.8 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.8.1 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.2.8.8.2 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.2.8.8.3 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.2.8.8.4 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.2.8.8.5 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.2.8.8.6 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.3 Asia Pacific Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028

12.3.1 Overview

12.3.2 Asia Pacific Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.3 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.4 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.5 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.6 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.7 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8 Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Country (2022 & 2028)

12.3.8.1 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.1.1 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.1.2 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.1.3 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.1.4 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.1.5 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.1.6 Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.2 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.2.1 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.2.2 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.2.3 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.2.4 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.2.5 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.2.6 China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.3 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.3.1 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.3.2 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.3.3 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.3.4 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.3.5 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.3.6 India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.4 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.4.1 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.4.2 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.4.3 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.4.4 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.4.5 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.4.6 South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.5 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.5.1 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.5.2 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.5.3 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.5.4 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.5.5 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.5.6 Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.6 New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.6.1 New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.6.2 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.6.3 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.6.4 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.6.5 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.6.6 New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.7 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.7.1 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.7.2 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.7.3 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.7.4 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.7.5 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.7.6 Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.8 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.8.1 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.8.2 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.8.3 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.8.4 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.8.5 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.8.6 Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.9 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.9.1 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.9.2 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.9.3 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.9.4 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.9.5 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.9.6 Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.10 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.10.1 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.10.2 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.10.3 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.10.4 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.10.5 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.10.6 Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.11 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.11.1 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.11.2 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.11.3 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.11.4 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.11.5 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.11.6 Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.3.8.12 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

12.3.8.12.1 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market– Revenue and Forecast to 2028 (US$ Million)

12.3.8.12.2 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

12.3.8.12.3 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

12.3.8.12.4 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

12.3.8.12.5 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

12.3.8.12.6 Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

12.4 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast To 2028

12.4.1 Overview

12.4.2 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.3 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.4 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.5 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.6 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.7 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8 Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

12.4.8.1 UAE: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.1.1 Overview

12.4.8.1.2 UAE: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.1.3 UAE: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.1.4 UAE: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.1.5 UAE: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.1.6 UAE: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.1.7 UAE: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.2.1 Overview

12.4.8.2.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.2.3 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.2.4 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.2.5 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.2.6 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.2.7 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8.3 South Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.3.1 Overview

12.4.8.3.2 South Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.3.3 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.3.4 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.3.5 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.3.6 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.3.7 South Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8.4 Iran: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.4.1 Overview

12.4.8.4.2 Iran: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.4.3 Iran: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.4.4 Iran: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.4.5 Iran: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.4.6 Iran: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.4.7 Iran: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8.5 Turkey: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.5.1 Overview

12.4.8.5.2 Turkey: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.5.3 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.5.4 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.5.5 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.5.6 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.5.7 Turkey: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.6.1 Overview

12.4.8.6.2 Kuwait: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.6.3 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.6.4 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.6.5 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.6.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.6.7 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.4.8.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.4.8.7.1 Overview

12.4.8.7.2 Bahrain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.4.8.7.3 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.4.8.7.4 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.4.8.7.5 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.4.8.7.6 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.4.8.7.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

LIST OF TABLES.

Table 1. North America Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 3. North America Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 4. North America Human Papillomavirus (HPV) Vaccine Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 5. North America Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 6. US Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 7. US Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 8. US Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 9. US Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 10. US Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 11. Canada: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 12. Canada Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 13. Canada Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 14. Canada Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 15. Canada Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 16. Mexico: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 17. Mexico Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 18. Mexico Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 19. Mexico Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 20. Mexico Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 21. Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 22. Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 23. Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 24. Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 25. Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 26. Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 27. Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 28. Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 29. Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 30. Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 31. France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 32. France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 33. France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 34. France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 35. France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 36. UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 37. UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 38. UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 39. UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 40. UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 41. Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 42. Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 43. Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 44. Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 45. Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 46. Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 47. Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 48. Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 49. Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 50. Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 51. Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 52. Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 53. Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 54. Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 55. Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 56. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 57. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 58. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 59. Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 60. Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 61. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 62. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 63. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 64. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 65. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 66. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 67. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 68. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 69. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 70. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 71. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 72. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 73. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 74. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 75. Japan: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 76. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 77. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 78. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 79. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 80. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 81. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 82. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 83. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 84. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 85. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 86. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 87. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 88. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 89. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 90. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 91. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 92. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 93. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 94. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 95. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 96. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 97. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 98. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 99. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 100. New Zealand : Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 101. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 102. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 103. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 104. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 105. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 106. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 107. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 108. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 109. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 110. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 111. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 112. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 113. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 114. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 115. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 116. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 117. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 118. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 119. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 120. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 121. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 122. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 123. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 124. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 125. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 126. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Type (US$ Million)

Table 127. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Dosage (US$ Million)

Table 128. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Age (US$ Million)

Table 129. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Application (US$ Million)

Table 130. Rest of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by End User (US$ Million)

Table 131. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 132. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 133. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 134. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 135. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 136. UAE Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 137. UAE Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 138. UAE Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 139. UAE Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 140. UAE Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 141. Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 142. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 143. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 144. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 145. Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 146. South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 147. South Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 148. South Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 149. South Africa Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 150. South Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 151. Iran: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 152. Iran Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 153. Iran Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 154. Iran Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 155. Iran Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 156. Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 157. Turkey Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 158. Turkey Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 159. Turkey Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 160. Turkey Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 161. Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 162. Kuwait Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 163. Kuwait Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 164. Kuwait Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 165. Kuwait Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 166. Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 167. Bahrain Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 168. Bahrain Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 169. Bahrain Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 170. Bahrain Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 171. Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 172. Egypt Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 173. Egypt Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 174. Egypt Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 175. Egypt Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 176. Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 177. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 178. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 179. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 180. Rest of Middle East & Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 181. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million).

Table 182. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 183. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 184. South & Central America: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 185. South & Central America: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 186. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 187. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 188. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 189. Argentina: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 190. Argentina: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 191. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 192. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 193. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 194. Brazil: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 195. Brazil: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 196. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 197. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 198. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 199. Chile: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 200. Chile: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 201. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 202. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 203. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 204. Guatemala: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 205. Guatemala: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 206. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 207. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 208. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 209. Peru: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 210. Peru: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 211. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 212. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 213. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 214. Colombia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 215. Colombia: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 216. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Type (US$ Million)

Table 217. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Dosage (US$ Million)

Table 218. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Age (US$ Million)

Table 219. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 220. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market, by End User– Revenue and Forecast to 2028 (US$ Million)

Table 221. Recent Inorganic Growth Strategies in the HPV Vaccines Market

Table 222. Recent Organic Growth Strategies in the HPV Vaccines Market

Table 223. Glossary of Terms

LIST OF FIGURES.

Figure 1. Human Papillomavirus (HPV) Vaccines Market Segmentation

Figure 2. Human Papillomavirus (HPV) Vaccines Market, By Region

Figure 3. Global Human Papillomavirus (HPV) Vaccine Market Overview

Figure 4. 9-Valent HPV Vaccine Segment Held Largest Share of Type Segment in Human Papillomavirus (HPV) Vaccines Market

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Human Papillomavirus (HPV) Vaccine Market, by Geography (US$ Million)

Figure 7. Global Human Papillomavirus (HPV) Vaccine Market - Leading Country Markets (US$ Million)

Figure 8. Global Human Papillomavirus (HPV) Vaccine Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East and Africa: PEST Analysis

Figure 13. South And Central America: PEST Analysis

Figure 14. Experts Opinion

Figure 15. Global Human Papillomavirus (HPV) Vaccines Market Impact Analysis of Driver and Restraints

Figure 16. Global Human Papillomavirus (HPV) Vaccine Market– Revenue Forecast and Analysis – 2022 - 2028

Figure 17. Global HPV Vaccines Market – By Geography Forecasts And Analysis – 2022- 2028

Figure 18. Global Human Papillomavirus (HPV) Vaccine Market – Market Potential Analysis, By Region

Figure 19. Global HPV Vaccines market – Growth Strategy Analysis

Figure 20. By Type: Market Analysis and Forecast 2022 and 2028 (%)

Figure 21. 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 22. Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 23. Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 24. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)

Figure 25. 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)

Figure 28. 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29. to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)

Figure 31. HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32. Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33. Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)

Figure 34. Doctor Office Market Revenue and Forecast to 2028 (US$ Million)

Figure 35. Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)

Figure 36. School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)

Figure 37. Health Departments Market Revenue and Forecast to 2028 (US$ Million)

Figure 38. Hospitals Market Revenue and Forecast to 2028 (US$ Million)

Figure 39. Others Market Revenue and Forecast to 2028 (US$ Million)

Figure 40. North America: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)

Figure 41. North America Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 42. North America: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

Figure 43. US: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 44. Canada: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. Mexico: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. Europe: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)

Figure 47. Europe: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 48. Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

Figure 49. Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 50. France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 51. UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 52. Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 53. Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 54. Russia Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 55. Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 56. Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 57. Asia Pacific Human Papillomavirus (HPV) Vaccines Market Overview, by Country (2022)

Figure 58. Asia Pacific Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 59. Asia Pacific: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028, by Country (2022 & 2028)

Figure 60. Japan Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 61. China: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 62. India: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 63. South Korea: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 64. Australia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 65. New Zealand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 66. Philippines: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 67. Thailand: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 68. Malaysia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 69. Singapore: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 70. Indonesia: Human Papillomavirus (HPV) Vaccines Market Revenue and Forecast to 2028 (US$ Million)

Figure 71. Rest Of Asia Pacific: Human Papillomavirus (HPV) Vaccines Market– Revenue and Forecast to 2028 (US$ Million)

Figure 72. Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)

Figure 73. Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 74. Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

Figure 75. UAE: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 76. Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 77. South Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 78. Iran: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 79. Turkey: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 80. Kuwait: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 81. Bahrain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 82. Egypt: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 83. Rest of Middle East & Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 84. South & Central America Human Papillomavirus (HPV) Vaccine Market Overview, by Country (2022)

Figure 85. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 86. South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028, By Country (%)

Figure 87. Argentina: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 88. Brazil: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 89. Chile: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 90. Guatemala: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 91. Peru: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 92. Colombia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 93. Rest of South & Central America: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecasts to 2028 (US$ Million)

Figure 94. Impact of COVID-19 Pandemic in North American Country Markets

Figure 95. Impact of COVID-19 Pandemic in European Country Markets

Figure 96. Impact of COVID-19 Pandemic on Asia Pacific Country Markets

Figure 97. Impact of COVID-19 Pandemic on Middle East & African Countries

Figure 98. Impact of COVID-19 Pandemic on South & Central America Countries

Figure 99. Growth Strategies in the HPV Vaccines Market, 2021-2028

List of Companies:

1. Merck & Co. In.

2. GSK

3. Serum Institute of India

4. Walvax Biotechnologies

5. Innova

6. Vaccitech

7. Innovio Pharmaceuticals

8. Chengdu Institute of Biological Products Co., Ltd.

9. Sanofi

10. R-Pharm

11. Shanghai Bowei

12. Bioleaders

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the human papillomavirus vaccine market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global human papillomavirus vaccine market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TOP